Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis

被引：136

作者：

Dev, Kumlesh K. ^{[1
,2
]}

Mullershausen, Florian ^{[3
]}

Mattes, Henri ^{[2
]}

Kuhn, Rainer R. ^{[2
]}

Bilbe, Graeme ^{[2
]}

Hoyer, Daniel ^{[2
]}

Mir, Anis ^{[2
]}

机构：

[1] Natl Univ Ireland Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland

[2] Nova Pharmaceut, Novartis Inst BioMed Res, Dept Neurosci, Basel, Switzerland

[3] Nova Pharmaceut, Novartis Inst BioMed Res, Dept G Prot Coupled Receptors, Basel, Switzerland

来源：

PHARMACOLOGY & THERAPEUTICS | 2008年 / 117卷 / 01期

关键词：

sphingosine-1-phosphate; SIP receptor; FTY720 (fingolimod); central nervous system; multiple sclerosis;

D O I：

10.1016/j.pharmthera.2007.08.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The current therapies available for MS work by all immunomodulatory action, preventing T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and axonal loss. Recently, FTY720 (fingolimod) was shown to significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials. This drug attenuates trafficking of harmful T cells entering the brain by regulating sphingosine-1-phosphate (SIP) receptors. Here, we outline the direct roles that S I P receptors play in the central nervous system (CNS) and discuss additional modalities by which FTY720 may provide direct neuroprotection in MS. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：77 / 93

页数：17

共 50 条

[21] Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article
Cohan, Stanley
Lucassen, Elisabeth
Smoot, Kyle
Brink, Justine
Chen, Chiayi
BIOMEDICINES, 2020, 8 (07)
[22] A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis
Saida, T.
Kikuchi, S.
Itoyama, Y.
Hao, Q.
Kurosawa, T.
Nagato, K.
Tang, D.
Zhang-Auberson, L.
Kira, J.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (09) : 1269 - 1277
[23] The sphingosine-1-phosphate receptor agonist FTY720 and its phosphorylated form affect the function of CD4+CD25+ T cells in vitro
Liu, Yong
Jiang, Jingjing
Xiao, He
Wang, Xiaokui
Li, Yan
Gong, Yubo
Huang, Yifei
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 30 (01) : 211 - 219
[24] Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, Volker
Billich, Andreas
Baumruker, Thomas
Heining, Peter
Schmouder, Robert
Francis, Gordon
Aradhye, Shreeram
Burtin, Pascale
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (11) : 883 - 897
[25] Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process
Yazdi, Azadeh
Ghasemi-Kasman, Maryam
Javan, Mohammad
JOURNAL OF NEUROSCIENCE RESEARCH, 2020, 98 (03) : 524 - 536
[26] Oral fingolimod in multiple sclerosis. Therapeutic modulation of the sphingosine-1-phosphate system
Aktas, O.
Ingwersen, J.
Kieseier, B.
Kuery, P.
Hohlfeld, R.
Hartung, H. -P.
NERVENARZT, 2011, 82 (02): : 215 - 225
[27] Sphingosine-1-phosphate receptors and innate immunity
Bryan, Arielle M.
Del Poeta, Maurizio
CELLULAR MICROBIOLOGY, 2018, 20 (05)
[28] Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (Fingolimod) in multiple sclerosis
Chang Wook Lee
Ji Woong Choi
Jerold Chun
Archives of Pharmacal Research, 2010, 33 : 1567 - 1574
[29] Neurological S1P Signaling as an Emerging Mechanism of Action of Oral FTY720 (Fingolimod) in Multiple Sclerosis
Lee, Chang Wook
Choi, Ji Woong
Chun, Jerold
ARCHIVES OF PHARMACAL RESEARCH, 2010, 33 (10) : 1567 - 1574
[30] Presynaptic Release-Regulating Sphingosine 1-Phosphate 1/3 Receptors in Cortical Glutamatergic Terminals: Adaptations in EAE Mice and Impact of Therapeutic FTY720
Roggeri, Alessandra
Olivero, Guendalina
Usai, Cesare
Vanmierlo, Tim
Pittaluga, Anna
CELLS, 2023, 12 (19)

← 1 2 3 4 5 →